PIK3CG and acute myeloid leukemia: Unlike AML cell lines with low PIK3R5 and PIK3CG, cells highly expressing PIK3R5 or PIK3CG are more sensitive to their loss and treatment with the PI3Kγ inhibitor eganelisib.